Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder
- Authors
- Lee, Soyoung Irene; Song, Dong-Ho; Shin, Dong Won; Kim, Ji Hoon; Lee, Young Sik; Hwang, Jun-Won; Park, Tae Won; Yook, Ki-Hwan; Lee, Jong Il; Bahn, Geon Ho; Hirata, Yuko; Goto, Taro; Takita, Yasushi; Takahashi, Michihiro; Lee, Sanghoon; Treuer, Tamas
- Issue Date
- Dec-2014
- Publisher
- WILEY-BLACKWELL
- Keywords
- ADHD; atomoxetine; executive function; Korea; quality of life
- Citation
- ASIA-PACIFIC PSYCHIATRY, v.6, no.4, pp 386 - 396
- Pages
- 11
- Journal Title
- ASIA-PACIFIC PSYCHIATRY
- Volume
- 6
- Number
- 4
- Start Page
- 386
- End Page
- 396
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11535
- DOI
- 10.1111/appy.12160
- ISSN
- 1758-5864
1758-5872
- Abstract
- IntroductionThis article aims to assess the efficacy and safety of atomoxetine in Korean adults with attention-deficit hyperactivity disorder (ADHD). MethodsThis post hoc double-blind, placebo-controlled study of atomoxetine (40-120mg/day) over 10 weeks in adults with ADHD at 45 Japanese, Korean, and Taiwanese study sites focused on patient data from Korea (atomoxetine, n=37; placebo, n=37). Primary efficacy outcome was change in baseline-to-endpoint Conners' Adult ADHD Rating Scale-Investigator-rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms score. Secondary efficacy outcomes included changes in Adult ADHD Quality of Life (AAQoL) total, Behavior Rating Inventory of Executive Function-Adult Version Self-Report (BRIEF-A:Self-Report), and Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) scale scores. ResultsAtomoxetine-treated patients demonstrated a mean 18.9-point reduction in CAARS-Inv:SV total ADHD Symptoms score, compared with the 7.45-point reduction in placebo-treated patients (P0.01). Significantly greater improvement was found for atomoxetine versus placebo in CGI-ADHD-S (P0.01), BRIEF-A:Self-Report global executive composite (P0.05), and metacognition index (P0.01) executive function scores. Nausea, decreased appetite, and dry mouth were reported with significantly greater frequency by atomoxetine-treated patients, and only one placebo-treated patient discontinued because of adverse event. A 2.1-kg reduction in weight and a 7.5-beat/minute increase in pulse rate were observed in atomoxetine-treated patients. DiscussionThese data support a significant benefit of 80- to 120-mg once daily atomoxetine versus placebo for treatment of ADHD in adult Korean patients. A high placebo response rate was observed in this adult Korean sample; a higher discontinuation rate was also observed in atomoxetine-treated patients. These observations warrant further investigation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11535)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.